158 results on '"Tewari, Priti"'
Search Results
2. Incidence and risk factors of early onset VOD/SOS differ in younger vs older adults after stem cell transplantation
3. Combination low-intensity chemotherapy plus inotuzumab ozogamicin, blinatumomab and rituximab for pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia
4. Biological Markers of High-Risk Childhood Acute Lymphoblastic Leukemia
5. Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia
6. Guidelines for Pediatric Unrelated Cord Blood Transplantation—Unique Considerations
7. Histologic Grade 1 Is Associated With Increased Nonrelapsed Mortality in Lower Gastrointestinal Graft Versus Host Disease
8. Transfusion reactions in pediatric and adolescent young adult haematology oncology and immune effector cell patients
9. P1299: OUTCOMES OF YOUNG ADULTS (AGED ≤40 YEARS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UPFRONT AUTOLOGOUS STEM CELL TRANSPLANT
10. Prognostic Analysis of Absolute Lymphocyte and Monocyte Counts after Autologous Stem Cell Transplantation in Children, Adolescents, and Young Adults with Refractory or Relapsed Hodgkin Lymphoma
11. Combining CAR T Cell Therapy and Oncolytic Virotherapy for Pediatric Solid Tumors: A Promising Option
12. Translational advances in the treatment of childhood acute lymphoblastic leukemia: narrative review of current and emerging molecular and immunotherapies
13. Characteristics and Outcomes of Children, Adolescents and Young Adults with Relapsed/Refractory Non-Hodgkin Lymphoma Undergoing First Autologous Hematopoietic Stem Cell Transplant
14. Classical Hodgkin Lymphoma: From Past to Future—A Comprehensive Review of Pathophysiology and Therapeutic Advances.
15. Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation
16. A multicenter study of ICU resource utilization in pediatric, adolescent and young adult patients post CAR-T therapy
17. The Evolution of Chimeric Antigen Receptor T-Cell Therapy in Children, Adolescents and Young Adults with Acute Lymphoblastic Leukemia
18. Post-Transplant Cyclophosphamide after Matched Sibling and Unrelated Donor Hematopoietic Stem Cell Transplantation in Pediatric Patients with Acute Myeloid Leukemia
19. Donor-derived multiple leukemia antigen–specific T-cell therapy to prevent relapse after transplant in patients with ALL
20. Implementing Rounding Checklists in a Pediatric Oncologic Intensive Care Unit
21. Pediatric, Adolescent and Young Adult Patients with Acute Myeloid Leukemia and DNMT3A Mutations May Have Improved Survival with Allogeneic Hematopoietic Stem Cell Transplant
22. Cell Surface Vimentin-Positive Circulating Tumor Cells May Predict Disease Relapse Post Hematopoietic Stem Cell Transplantation or Cellular Therapy in Patients with Hematological Malignancies
23. Totally Excited about Moving Mobility and Exercise (TEAM Me): A Successful Multidisciplinary Exercise Quality Improvement Initiative for Pediatric and Young Adult Oncology and Stem Cell Transplant Inpatients
24. Myeloablative Transplantation using either Cord Blood or Bone Marrow leads to Immune Recovery, High Long-Term Donor Chimerism and Excellent Survival in Chronic Granulomatous Disease
25. Cardiac Relapse of Acute Lymphoblastic Leukemia Following Hematopoietic Stem Cell Transplantation: A Case Report and Review of Literature
26. DNMT3A Mutations Should be Considered in the Risk Stratification for Pediatric and Adolescent and Young Adult Patients with Acute Myeloid Leukemia
27. Immune Effector Cell Associated Neurotoxicity (ICANS) in Pediatric and Young Adult Patients Following Chimeric Antigen Receptor (CAR) T-Cell Therapy: Can We Optimize Early Diagnosis?
28. Case Discussion and Literature Review: Cancer Immunotherapy, Severe Immune-Related Adverse Events, Multi-Inflammatory Syndrome, and Severe Acute Respiratory Syndrome Coronavirus 2
29. IMMU-07. IMMUNE EFFECTOR CELL ASSOCIATED NEUROTOXICITY (ICANS) AMONG PEDIATRIC AND AYA PATIENTS: MD ANDERSON CANCER CENTER EXPERIENCE
30. IMMU-52. IMMUNE EFFECTOR CELL ASSOCIATED NEUROTOXICITY (ICANS) AMONG PEDIATRIC AND AYA PATIENTS: MD ANDERSON CANCER CENTER EXPERIENCE
31. Chimeric Antigen Receptor, Teamwork, Education, Assessment, and Management (CAR-TEAM): A Simulation-Based Inter-professional Education (IPE) Intervention for Management of CAR Toxicities
32. Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD‐19 chimeric antigen receptor T‐cell therapy
33. Transfusion Reactions in Pediatric and Young Adult Hematopoietic Stem Cell Transplant and Oncology Patients
34. Immune Effector Cell Associated Neurotoxicity (ICANS) Among Pediatric and AYA Patients: MD Anderson Cancer Center Experience
35. Sinusoidal Obstructive Syndrome Among Pediatric and Adolescent and Young Adult Patients: Analysis of Pediatric EBMT Diagnostic and Severity Criteria at MD Anderson
36. 560 - Cell Surface Vimentin-Positive Circulating Tumor Cells May Predict Disease Relapse Post Hematopoietic Stem Cell Transplantation or Cellular Therapy in Patients with Hematological Malignancies
37. 456 - Immune Reconstitution Following Tisagenlecleucel in Pediatric, Adolescent and Young Adult (AYA) Patients with Relapsed Refractory (R/R) B Acute Lymphoblastic Leukemia (B ALL)
38. 461 - Quantitative and Qualitative Immune Reconstitution Analysis in an Adolescent Patient with Refractory Primary Mediastinal Large B Cell Lymphoma after Axicabtagene Ciloleucel CD19 CAR T-Cell Therapy
39. 162 - Pediatric, Adolescent and Young Adult Patients with Acute Myeloid Leukemia and DNMT3A Mutations May Have Improved Survival with Allogeneic Hematopoietic Stem Cell Transplant
40. Myeloablative Conditioning with Alemtuzumab in Matched Related Donor Hematopoietic Cell Transplant for Sickle Cell Disease Prevents Graft-Versus-Host Disease without Compromising Engraftment
41. The Effectiveness of the Neutropenic Diet in Pediatric Bone Marrow Transplant Patients
42. Myeloablative Conditioning with Alemtuzumab in Matched Related Donor Hematopoietic Cell Transplant for Sickle Cell Disease Prevents Graft-Versus-Host Disease without Compromising Engraftment
43. Bacteremia While Receiving Chemotherapy Prior to Stem Cell Infusion is Uncommon Despite Frequent Use of Empiric Antibiotics: Results of a Multi-Institutional Analysis
44. Outcomes of Umbilical Cord Transplant (UCBT) Conditioned Without Serotherapy for Pediatric Malignant and Non-Malignant Diseases: Texas Children's Hospital Experience
45. Cord Blood Transplant for Very High Risk Hematologic Malignancies in Children Using Conditioning Without Serotherapy
46. Use of Granulocyte Infusion are Safe and Maybe a Beneficial Supportive Care Modality for Stem Cell Transplant Recipients
47. High TCR Vbeta Skewing in CD4+ and Low in CD8+ Is Associated with Development of Chronic Graft-Versus-Host Disease
48. Analysis of the Prognostic Effect of Peripheral Blood Lymphocyte and Monocyte Count after Autologous Hematopoietic Stem Cell Transplant in Refractory/Relapsed Hodgkin's Lymphoma in a Pediatric, Adolescent, and Young Adult Population
49. Prospective Phase 2 Trial of High-Dose Gemcitabine/Busulfan/Melphalan (Gem/Bu/Mel) with Autologous Stem-Cell Transplant (ASCT) without Post-ASCT Maintenance, in Hodgkins Lymphoma Patients at High Risk of Post-Transplant Recurrence Comparison with a Concurrent Matched Cohort Treated with BEAM
50. 609 - Cord Blood Transplant for Very High Risk Hematologic Malignancies in Children Using Conditioning Without Serotherapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.